Folate Alpha Targeting: Exciting New Options for Platinum Resistance Ovarian Cancer Patients-Folate Alpha Targeting: Exciting New Options for Platinum Resistance Ovarian Cancer Patients

Folate Alpha Targeting: Exciting New Options for Platinum Resistance Ovarian Cancer Patients

Video Transcription

Video Summary

In this video, Rob Coleman, a gynecologic oncologist, welcomes viewers to a live broadcast from the NRG-GOG meeting in Chicago. He introduces himself as the president of the International Gynecologic Cancer Society (IGCS) and expresses gratitude to Immunogen for their partnership and support. The video focuses on the topic of folate receptor alpha and targeting in precision medicine. The discussion covers antibody drug conjugates, preliminary data, clinical experience, efficacy, toxicities, and future directions. Two experts, Kathleen Moore and Dave O'Malley, join Coleman in discussing the subject. They explain that folate receptor alpha is a target for ovarian cancer treatment and discuss its expression and importance in patient response. They also mention the Mirasol and Soreyes studies, highlighting their study designs, eligibility criteria, response rates, and toxicity profiles. The video concludes with a brief mention of the development plans for Mervatuximab, with the goal of replacing paclitaxel in ovarian cancer treatment and expanding its use into different diseases and treatment settings. The video acknowledges Immunogen for their support and encourages viewers to attend the upcoming IGCS conference in New York City. No specific credits are mentioned in the video.

Keywords

gynecologic oncologist

folate receptor alpha

precision medicine

ovarian cancer treatment

clinical experience

toxicity profiles

Mervatuximab

IGCS conference